Myocardial infarction secondary prevention study (MISPS)
- Author:
Hongcai SHANG
;
Guohua DAI
;
Junhua HANG
;
Yaozu XIANG
;
Yang WANG
;
Junping ZHANG
;
Wuxun DU
;
Jingyuan MAO
;
Chen YAO
;
Weiliang WENG
;
Tiancai WEN
;
Boli ZHANG
- Publication Type:Journal Article
- From:Journal of Geriatric Cardiology
2006;3(2):116-119
- CountryChina
- Language:Chinese
-
Abstract:
Background Traditional Chinese medicine (TCM), especially herbal medicine, has been widely used in China and now is also being increasingly used in other countries for the treatment of cardiovascular diseases. Although many studies have demonstrated that certain Chinese herbal products are effective and safe for the treatment of cardiovascular diseases, most of these lack sufficient quality. Therefore, large randomized clinical trials and further scientific research to determine its safety, effectiveness are necessary.QiShen YiQi Dripping Pills (QSYQDP) is a herbal preparation clinically used in the treatment and prevention of coronary artery disease. Preliminary observations have shown its safety and effectiveness. Methods/Design This randomized, controlled trial will recruit 3600 patients with a history of myocardial infarction. Patients will be randomized into two groups by a Centr-Randomized System. One group receives QSYQDP, the other group receive aspirin. This trial protocol will describe eligibility criteria, detailed information on the treatment definition, blinding, endpoints, statistical methods, sample size determination, data management, legal aspects, and the current status of the trial. Discussion This trial is one of the first randomized, controlled clinical trial to evaluate the efficacy and safety of traditional Chinese herbal medicine in the treatment and secondary prevention of coronary artery disease. The results of this study should help to define the role of TCM in modern medical care, as well as to provide the management strategy for CAD patients in China and other countries.
